309 results on '"Della Porta, Matteo Giovanni"'
Search Results
2. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
3. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
4. A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications
5. Using real-world evidence in haematology
6. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
7. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
8. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
9. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
10. Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
11. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
12. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation
13. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
14. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
15. Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form?
16. Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis
17. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
18. A Rule-Based Expert System for Automatic Implementation of Somatic Variant Clinical Interpretation Guidelines
19. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML
20. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
21. Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes
22. Opportunities and Challenges of Synthetic Data Generation in Oncology
23. S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
24. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
25. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
26. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
27. Mutations in the splicing factor SF3B1are linked to frequent emergence of HLA-DRlow/negmonocytes in lower-risk myelodysplastic neoplasms
28. Breast and renal cancer—Derived endothelial colony forming cells share a common gene signature
29. Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
30. A Rule-Based Expert System for Automatic Implementation of Somatic Variant Clinical Interpretation Guidelines
31. Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant
32. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
33. SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia
34. MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
35. SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
36. The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence
37. SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia.
38. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
39. Generative Adversarial Networks in Brain Imaging: A Narrative Review
40. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues
41. PBX1-directed stem cell transcriptional program drives tumor progression in myeloproliferative neoplasm
42. The Genetics of Myelodysplastic Syndromes: Clinical Relevance
43. Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes
44. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
45. Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors
46. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
47. Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes
48. Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project
49. Mutated clones driving leukemic transformation are already detectable at the single cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
50. Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.